Finanzen von Oruka Therapeutics Inc (ORKA)ORKAOruka Therapeutics Inc

Evaluating the bottom line, Oruka Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -18.30%, provide a clear picture of how effectively ORKA converts its operational activities into shareholder value.

In the context of the broader market, ORKA competes directly with industry leaders such as MIRM and PTCT. With a market capitalization of $5.98B, it holds a leading position in the sector. When comparing efficiency, ORKA's gross margin of N/A stands against MIRM's 82.78% and PTCT's 91.19%. Such benchmarking helps identify whether Oruka Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Oruka has shown substantial growth with a year-to-date change of +183.52% and a one-year change of +189.35%. Despite this, the company is currently experiencing net losses, with EPS reported at -0.55 for the last quarter.